Inhibikase Therapeutics, Inc. Share Price & Technical Analysis
IKT · $1.69 (-2.87%)
Healthcare / Biotechnology
$1.69
-2.87%
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imat…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-11% return in May, 13% avg return in past 3 year May month.
-5% return in 2026, 38% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -29% | 33% | -11% | 12% | -11% | – | – | – | – | – | – | – | -5% |
| 25 | -34% | 5% | -4% | 5% | -13% | 0% | -20% | 13% | -11% | -6% | 0% | 33% | -34% |
| 24 | 131% | -27% | 0% | -32% | 29% | -37% | 17% | 0% | -7% | 92% | 16% | 7% | 189% |
| 23 | 45% | 2% | -17% | -13% | 24% | -10% | -24% | -23% | -33% | -36% | 0% | 44% | -40% |
| 22 | -8% | -24% | 44% | -25% | -14% | -18% | 19% | 12% | -10% | -18% | -27% | -19% | -88% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$255.48M
P/E ratio
—
52W high
$2.26
52W low
$1.33
Volume
5,12,162
Beta
0.96
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Inhibikase Therapeutics, Inc. share price today?
- Inhibikase Therapeutics, Inc. (IKT) last traded around $1.69 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IKT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IKT. Download the app for real-time alerts.
- How can I analyze Inhibikase Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.